![](https://www.myelomasociety.org/wp-content/uploads/2024/04/Karl-Petri.jpg)
USB|CAR-T: Using CRISPR 2.0 to Generate Universal SLAMF7/BCMA CAR-T Cells for Treating Multiple Myeloma
Basic Information
Description
The project focuses on developing a novel CAR-T cell therapy aimed at treating multiple myeloma by utilizing advanced gene editing technologies to engineer a universal CAR-T cell product targeting SLAMF7 and BCMA. The approach involves strategic gene modifications to enhance the therapy’s compatibility and effectiveness while minimizing immune rejection and reducing the risk of adverse reactions.